Comparison Of The Efficacy And Safety Of Secukinumab, Ustekinumab And Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis: A Systematic Review
Journal of Pharmaceutical Negative Results
; 14(2):485-495, 2023.
Article
in English
| EMBASE | ID: covidwho-2240425
ABSTRACT
Psoriasis is a chronic inflammatory skin condition characterized by scaly erythematous patches or plaques affecting the extensor surfaces that are prominent but spreading to all areas of the body, including the flexor surfaces. Psoriasis occurs when the body's immune system attacks the skin;the interleukin (IL)-12 and IL-17/23 axes play a major role in its pathogenesis. Biologic therapies targeting IL-17 or IL-23 have emerged as an important treatment option for psoriasis and have led to substantial improvements in patients' quality of life. This systematic review aimed to evaluate the comparative efficacy and safety of secukinumab, ustekinumab and guselkumab for the treatment of moderate to severe plaque psoriasis. Based on the final analysis, there were 10 articles, namely 5 RCTs and 5 observational. We found that patients who were given secukinumab showed a rapid response, whereas guselkumab was superior in terms of long-term response (approximately 1 year) and complete remission compared to other biologics. Among all the biologics assessed, ustekinumab showed relatively low efficacy.
guselkumab; risankizumab; secukinumab; ustekinumab; acute heart infarction; allergy; arthralgia; article; candidiasis; connective tissue disease; controlled study; coronavirus disease 2019; diarrhea; drug efficacy; drug safety; drug substitution; drug withdrawal; flu like syndrome; follow up; headache; human; hypertension; infection; injection site reaction; musculoskeletal disease; psoriasis; psoriasis vulgaris; randomized controlled trial (topic); respiratory tract infection; rhinopharyngitis; systematic review; tinea capitis; upper respiratory tract infection
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
Journal of Pharmaceutical Negative Results
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS